MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Bimatoprost/timolol
Glaucoma
Intraocular pressure
Netarsudil/latanoprost
Rho-kinase inhibitor
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
24 Aug 2023
24 Aug 2023
Historique:
received:
25
03
2023
accepted:
23
07
2023
revised:
22
06
2023
pubmed:
24
8
2023
medline:
24
8
2023
entrez:
24
8
2023
Statut:
aheadofprint
Résumé
PURPOSE : To compare the efficacy and safety of the fixed-dose combination (FDC) of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NET/LAT; Roclanda MERCURY-3 was a 6-month prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, non-inferiority study. Patients (≥ 18 years) with a diagnosis of OAG or OHT in both eyes that was insufficiently controlled with topical medication (IOP ≥ 17 mmHg in ≥ 1 eye and < 28 mmHg in both eyes) were included. Following washout, patients were randomized to once-daily NET/LAT or BIM/TIM for up to 6 months; efficacy was assessed at Week 2, Week 4, and Month 3; safety was evaluated for 6 months. Comparison of NET/LAT relative to BIM/TIM for mean IOP at 08:00, 10:00, and 16:00 h was assessed at Week 2, Week 6, and Month 3. Non-inferiority of NET/LAT to BIM/TIM was defined as a difference of ≤ 1.5 mmHg at all nine time points through Month 3 and ≤ 1.0 mmHg at five or more of nine time points through Month 3. Overall, 430 patients were randomized (NET/LAT, n = 218; BIM/TIM, n = 212), and all received at least one dose of study medication. Efficacy analyses were performed at Month 3 on 388 patients (NET/LAT, n = 184; BIM/TIM, n = 204). NET/LAT demonstrated non-inferiority to BIM/TIM, with a between-treatment difference in IOP of ≤ 1.5 mmHg achieved at all time points and ≤ 1.0 mmHg at the majority of time points (six of nine) through Month 3. Mean diurnal IOP during the study ranged from 15.4 to 15.6 mmHg and 15.2 to 15.6 mmHg in the NET/LAT and BIM/TIM groups respectively, with no between-group statistically significant difference. No significant differences were observed in key secondary endpoints. No serious, treatment-related adverse events (AEs) were observed, and AEs were typically mild/moderate in severity. The most common treatment-related AEs were conjunctival hyperemia (NET/LAT, 30.7%; BIM/TIM, 9.0%) and cornea verticillata (NET/LAT, 11.0%; BIM/TIM, 0%). Once-daily NET/LAT was non-inferior to BIM/TIM in IOP reduction in OAG and OHT, with AEs consistent with previous findings. NET/LAT offers a compelling alternative FDC treatment option for OAG and OHT.
Identifiants
pubmed: 37615697
doi: 10.1007/s00417-023-06192-0
pii: 10.1007/s00417-023-06192-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Kass MA, Heuer DK, Higginbotham EJ et al (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120:701–713. https://doi.org/10.1001/archopht.120.6.701
doi: 10.1001/archopht.120.6.701
pubmed: 12049574
Heijl A, Leske MC, Bengtsson B et al (2002) Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120:1268–1279. https://doi.org/10.1001/archopht.120.10.1268
doi: 10.1001/archopht.120.10.1268
pubmed: 12365904
Chauhan BC, Mikelberg FS, Balaszi AG et al (2008) Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 126:1030–1036. https://doi.org/10.1001/archopht.126.8.1030
doi: 10.1001/archopht.126.8.1030
pubmed: 18695095
European Glaucoma Society (2021) European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol 105:1–169
doi: 10.1136/bjophthalmol-2021-egsguidelines
Kazemi A, McLaren JW, Kopczynski CC et al (2018) The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans. J Ocul Pharmacol Ther 34:380–386. https://doi.org/10.1089/jop.2017.0138
doi: 10.1089/jop.2017.0138
pubmed: 29469601
pmcid: 5995263
Toris CB, Yablonski ME, Wang YL, Camras CB (1999) Aqueous humor dynamics in the aging human eye. Am J Ophthalmol 127:407–412. https://doi.org/10.1016/s0002-9394(98)00436-x
doi: 10.1016/s0002-9394(98)00436-x
pubmed: 10218693
McLaren NC, Moroi SE (2003) Clinical implications of pharmacogenetics for glaucoma therapeutics. Pharmacogenomics J 3:197–201. https://doi.org/10.1038/sj.tpj.6500181
doi: 10.1038/sj.tpj.6500181
pubmed: 12931133
Park JH, Chung HW, Yoon EG et al (2021) Morphological changes in the trabecular meshwork and Schlemm’s canal after treatment with topical intraocular pressure-lowering agents. Sci Rep 11:18169. https://doi.org/10.1038/s41598-021-97746-x
doi: 10.1038/s41598-021-97746-x
pubmed: 34518638
pmcid: 8437975
Shiroma LO, Costa VP (2015) Parasympathomimetics. In: Glaucoma (second edition) Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG (eds) Elsevier pp 577–582. https://doi.org/10.1016/B978-0-7020-5193-7.00056-X
Holló G, Topouzis F, Fechtner RD (2014) Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother 15:1737–1747. https://doi.org/10.1517/14656566.2014.936850
Holló G, Vuorinen J, Tuominen J et al (2014) Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther 31:932–944. https://doi.org/10.1007/s12325-014-0151-7
Denis P, Lafuma A, Berdeaux G (2004) Medical outcomes of glaucoma therapy from a nationwide representative survey. Clin Drug Investig 24:343–352. https://doi.org/10.2165/00044011-200424060-00004
doi: 10.2165/00044011-200424060-00004
pubmed: 17516721
Moura-Coelho N, Tavares Ferreira J et al (2019) Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology. Graefes Arch Clin Exp Ophthalmol 257:1101–1117. https://doi.org/10.1007/s00417-019-04283-5
doi: 10.1007/s00417-019-04283-5
pubmed: 30843105
Wang J, Liu X, Zhong Y (2013) Rho/Rho-associated kinase pathway in glaucoma (Review). Int J Oncol 43:1357–1367. https://doi.org/10.3892/ijo.2013.2100
doi: 10.3892/ijo.2013.2100
pubmed: 24042317
Berrino E, Supuran CT (2019) Rho-kinase inhibitors in the management of glaucoma. Expert Opin Ther Pat 29(10):817–827. https://doi.org/10.1080/13543776.2019.1670812
doi: 10.1080/13543776.2019.1670812
pubmed: 31573364
Schehlein EM, Robin AL (2019) Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment. Drugs 79:1031–1036. https://doi.org/10.1007/s40265-019-01130-z
doi: 10.1007/s40265-019-01130-z
pubmed: 31134520
Sit AJ, Gupta D, Kazemi A et al (2021) Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study. Am J Ophthalmol 226:262–269. https://doi.org/10.1016/j.ajo.2021.01.019
doi: 10.1016/j.ajo.2021.01.019
pubmed: 33524367
Xu H, Thomas MT, Lee D et al (2022) Response to netarsudil in goniotomy-treated eyes and goniotomy-naive eyes: a pilot study. Graefes Arch Clin Exp Ophthalmol 260:3001–3007. https://doi.org/10.1007/s00417-022-05609-6
doi: 10.1007/s00417-022-05609-6
pubmed: 35275261
Zaman F, Gieser SC, Schwartz GF et al (2021) A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting. Curr Med Res Opin 37:1011–1020. https://doi.org/10.1080/03007995.2021.1901222
doi: 10.1080/03007995.2021.1901222
pubmed: 33733980
Ren R, Li G, Le TD et al (2019) Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms. Invest Ophthalmol Vis Sci 57:6197–6209. https://doi.org/10.1167/iovs.16-20189
doi: 10.1167/iovs.16-20189
Asrani S, Bacharach J, Holland E et al (2020) Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2. Adv Ther 37:1620–1631. https://doi.org/10.1007/s12325-020-01277-2
doi: 10.1007/s12325-020-01277-2
pubmed: 32166538
pmcid: 7140751
Asrani S, Robin AL, Serle JB et al (2019) Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. Am J Ophthalmol 207:248–257. https://doi.org/10.1016/j.ajo.2019.06.016
doi: 10.1016/j.ajo.2019.06.016
pubmed: 31229466
Walters TR, Ahmed IIK, Lewis RA et al (2019) Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study. Ophthalmol Glaucoma 2:280–289. https://doi.org/10.1016/j.ogla.2019.03.007
doi: 10.1016/j.ogla.2019.03.007
pubmed: 32672669
Wong JC, Shiuey EJ, Razeghinejad R et al (2023) The effectiveness and tolerability of fixed-dose combination netarsudil 0.02%/latanoprost 0.005% at a tertiary glaucoma center. Graefes Arch Clin Exp Ophthalmol 261:193–200. https://doi.org/10.1007/s00417-022-05780-w
doi: 10.1007/s00417-022-05780-w
pubmed: 35904596
Brandt JD, Cantor LB, Katz LJ et al (2008) Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma 17:211–216. https://doi.org/10.1097/IJG.0b013e3181507313
doi: 10.1097/IJG.0b013e3181507313
pubmed: 18414107
Stewart WC, Konstas AG, Nelson LA, Kruft B (2008) Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 115:1117–1117-22 e1. https://doi.org/10.1016/j.ophtha.2007.10.004
doi: 10.1016/j.ophtha.2007.10.004
pubmed: 18082886
Takamura E, Uchio E, Ebihara N et al (2017) Japanese guidelines for allergic conjunctival diseases 2017. Allergol Int 66:220–229. https://doi.org/10.1016/j.alit.2016.12.004
doi: 10.1016/j.alit.2016.12.004
pubmed: 28209324
Singh IP, Fechtner RD, Myers JS et al (2020) Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension. J Glaucoma 29:878–884. https://doi.org/10.1097/IJG.0000000000001634
doi: 10.1097/IJG.0000000000001634
pubmed: 32826769
pmcid: 7647436
Holló G, Whitson JT, Faulkner R et al (2006) Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration. Invest Ophthalmol Vis Sci 47:235–240. https://doi.org/10.1167/iovs.05-0945
Holló G, Kothy P (2008) Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma. Curr Med Res Opin 24:1755–1761. https://doi.org/10.1185/03007990802159273
Konstas AG, Mylopoulos N, Karabatsas CH et al (2004) Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma. Eye (Lond) 18:893–899. https://doi.org/10.1038/sj.eye.6701345
doi: 10.1038/sj.eye.6701345
pubmed: 15002024
Radcliffe NM (2014) The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies. Clin Ophthalmol 8:2541–2549. https://doi.org/10.2147/OPTH.S76053
doi: 10.2147/OPTH.S76053
pubmed: 25540579
pmcid: 4270356
Raizman MB, Hamrah P, Holland EJ et al (2017) Drug-induced corneal epithelial changes. Surv Ophthalmol 62:286–301. https://doi.org/10.1016/j.survophthal.2016.11.008
doi: 10.1016/j.survophthal.2016.11.008
pubmed: 27890620
Wisely CE, Sheng H, Heah T, Kim T (2020) Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2. Adv Ther 37:1114–1123. https://doi.org/10.1007/s12325-020-01227-y
doi: 10.1007/s12325-020-01227-y
pubmed: 31981106
pmcid: 7089717